Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Europe's STOXX 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

In the latest trading session, Novo Nordisk (NVO) closed at $87.37, marking a -1.51% move from the previous day.

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In the past six months, shares of Novo Nordisk have plunged 39.6% compared with the industry’s decline of 17.7%. The stock has also underperformed the sector and the S&P 500 during the same time ...